semaglutide and side effects GLP-1 Semaglutide: Why Smart Biomarker Monitoring Matters Common Semaglutide Side Effects and

Hekimi, S., Wang, Y., & No, A

The phase III REDEFINE 1 study results, released in December 2024, showed that the CagriSema treatment group lost 22.7% of their weight after 68 weeks, significantly outperforming the single-target control drugs (semaglutide group lost 16.1%, cagrilintide group lost 11.8%)

Altitud: 1800-2000 msnm

The REWIND cardiovascular outcome trial also revealed that dulaglutide administration resulted in inferior ocular outcomes, leading to an increased need for interventions such as photocoagulation, anti-vascular endothelial growth factor (VEGF) therapy, or vitrectomy compared to placebo recipients [38]